Safety Issues Specific to Clinical Development of Protein Therapeutics
Authors:
- Ca HallerCHCa Haller
- Me CosenzaMCMe Cosenza
- Jt SullivanJSJt Sullivan
- 13 August 2008
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 84 (5) , 624-627
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequencesSupportive Care in Cancer, 2007
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Management and Preparedness for Infusion and Hypersensitivity ReactionsThe Oncologist, 2007
- A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugsNature Biotechnology, 2007
- Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodiesDrug Discovery Today, 2007
- Immunogenicity Issues in the Development of Therapeutic ProteinsInternational Journal of Pharmaceutical Medicine, 2007
- Biophysical Comparability of the Same Protein From Different Manufacturers: A Case Study Using Epoetin Alfa From Epogen® and Eprex®Journal of Pharmaceutical Sciences, 2006
- Eprex-associated pure red cell aplasia and leachatesNature Biotechnology, 2006
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002